Table 1.
Subject demographic data
| Patient | Age | Sex | Stage at start of treatment | ECOG performance status | Previous systemic therapies for melanoma | |
|---|---|---|---|---|---|---|
| AJCC | TNM | |||||
| 001001 | 63 | M | IV | M1a | 0 | Dacarbazine |
| 001002 | 76 | M | IV | M1c | 0 | Nab-paclitaxel |
| 001003 | 73 | F | IV | M1a | 0 | Dacarbazine |
| 001004 | 55 | M | IV | M1c | 1 | VMCL vaccinea |
| 001006 | 61 | M | IV | M1c | 1 | Dacarbazine |
| 001007 | 45 | F | IV | M1b | 0 | No prior systemic therapyb |
| 001008 | 28 | F | IV | M1c | 0 | BRAF inhibitor, ipilimumabc, dacarbazine |
| 001009 | 68 | M | IV | M1c | 0 | Nab-paclitaxel |
| 001010 | 78 | M | IV | M1c | 0 | No prior treatment |
| 001012 | 46 | F | IV | M1c | 0 | Nab-paclitaxel |
| 001013 | 70 | F | IV | M1c | 0 | Interferon therapy, dacarbazine |
| 001014 | 78 | M | IV | M1c | 0 | No prior systemic therapy |
AJCC American Joint Committee on Cancer staging (6th edition), TNM (Tumor Node Metastasis) stage, ECOG Eastern Cooperative Oncology Group
aPrevious immunotherapy (vaccine)—protocol violation
bPreviously received carboplatin, paclitaxel, 5-fluorouracil, methotrexate, cyclophosphamide and trastuzumab for ovarian and breast cancer
cRoyal Adelaide Hospital Human Research Ethics Committee granted a protocol waiver for previous immunotherapy (ipilimumab) because of the patient’s exceptional youth